Patent · US Active

AGR2 blocking antibody and use thereof

US9574012B2 · kind B2 · utility

1Cited by

1References

17Claims

0Family size

Assignees

Sanofi (China) Investment Co., Ltd. Shanghai Branch · CN
Shanghai Jiao Tong University · CN

Inventors

Dawei Li · Tangxia, CN
Zhenghua Wu · Shanghai, CN
Hao Guo · Los Angeles, US
Qi Zhu · Houston, US
Dhahiri S. Mashausi · Shanghai, CN

Key dates

Filing date	Jul 5, 2012
Grant date	Feb 21, 2017
Priority date	—
Expiry date	Dec 10, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.